10th Feb 2009 14:19
|
For Immediate Release |
10 February 2009 |
SkyePharma PLC ("the Company")
Additional Listing and Total Voting Rights
Application has been made to the UK Listing Authority and to the London Stock Exchange for an additional 269 Ordinary Shares of £1.00 each to be admitted to the Official List and to the London Stock Exchange's market for listed securities. The additional Ordinary Shares will rank pari passu in all respects with the existing Ordinary Shares.
These shares have been issued following the conversion of one 6% 2024 Convertible Bond at a conversion price of £3.71.
Following the issue, SkyePharma's issued share capital as at 12 February 2009 will consist of 22,167,964 Ordinary Shares with voting rights. No shares are held in treasury. Therefore, the total number of voting rights in the Company will be 22,167,964.
The above figure (22,167,964) may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.
Related Shares:
SKP.L